Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

T Cell Types and Functions01:24

T Cell Types and Functions

3.0K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
3.0K
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

1.4K
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
1.4K
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

1.3K
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
1.3K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

692
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
692
Renewal of Intestinal Stem Cells01:23

Renewal of Intestinal Stem Cells

3.5K
The intestinal epithelial lining rapidly renews every 4 to 5 days. The renewal is facilitated by intestinal stem cells (ISCs) located at the base of the crypt– a gland located at the bottom of each villus. ISCs divide asymmetrically to form new stem cells and progenitor daughter cells. The daughter cells are called transit-amplifying (TA) cells which move upwards along the crypt and either differentiate into absorptive cells– the enterocytes or secretory cells– including the...
3.5K
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

869
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
869

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

TIM3 Signaling in Effector T Cells Acts as an Immunometabolic Switch in the Purine Degradation Pathway to Suppress Intestinal Inflammation.

Gastroenterology·2026
Same author

Author Correction: Regulatory T cells in the mouse hypothalamus control immune activation and ameliorate metabolic impairments in high-calorie environments.

Nature communications·2026
Same author

Targeting the transcription factor GATA3 by the DNAzyme formulation SB012 in patients with moderately-to-severely active ulcerative colitis: a multicenter, randomized, placebo-controlled, phase 2a induction trial.

Inflammatory bowel diseases·2026
Same author

Early Gut-Vascular Barrier Breakdown Precedes Colitis Onset in Murine Models.

Cellular and molecular gastroenterology and hepatology·2026
Same author

Interaction of nanodrug delivery systems via fibroblasts in colorectal cancer.

Expert opinion on drug delivery·2025
Same author

Quercetin-Loaded Nanoparticles: A Promising Therapeutic Strategy for Inflammatory Bowel Disease.

Journal of inflammation research·2025

Related Experiment Video

Updated: Mar 12, 2026

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice
07:34

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice

Published on: December 16, 2021

3.3K

Th9 cells in inflammatory bowel diseases.

Benno Weigmann1, Markus F Neurath2

  • 1Department of Medicine 1, Kussmaul Campus for Medical Research, Ludwig Demling Endoscopy Center of Excellence, University of Erlangen-Nürnberg, Erlangen, Germany.

Seminars in Immunopathology
|November 13, 2016
PubMed
Summary

Interleukin-9 (IL-9) producing T cells worsen inflammatory bowel diseases by damaging the gut barrier. Blocking IL-9 shows promise for treating these chronic conditions.

Keywords:
CytokinesIBDIl-9Immune responseTh9 cellsTherapy

More Related Videos

Isolation and Characterization of Dendritic Cells and Macrophages from the Mouse Intestine
09:25

Isolation and Characterization of Dendritic Cells and Macrophages from the Mouse Intestine

Published on: May 21, 2012

40.0K
Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes
12:59

Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes

Published on: September 26, 2013

35.7K

Related Experiment Videos

Last Updated: Mar 12, 2026

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice
07:34

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice

Published on: December 16, 2021

3.3K
Isolation and Characterization of Dendritic Cells and Macrophages from the Mouse Intestine
09:25

Isolation and Characterization of Dendritic Cells and Macrophages from the Mouse Intestine

Published on: May 21, 2012

40.0K
Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes
12:59

Isolation and Th17 Differentiation of Naïve CD4 T Lymphocytes

Published on: September 26, 2013

35.7K

Area of Science:

  • Immunology
  • Gastroenterology
  • Molecular Biology

Background:

  • Inflammatory bowel diseases (IBD) are chronic, relapsing immune-mediated gastrointestinal disorders.
  • Transcription factors and T cell cytokines play a key role in IBD pathogenesis.
  • Increased levels of IL-9 producing T cells are observed in IBD patients.

Purpose of the Study:

  • To investigate the role of IL-9 producing T cells in IBD.
  • To evaluate the therapeutic potential of targeting IL-9 in experimental colitis models.

Main Methods:

  • Analysis of gut-residing T cells from IBD patients.
  • Utilizing experimental models of colitis.
  • Assessing the impact of IL-9 on intestinal epithelial barrier function, cellular proliferation, and tight junction molecules.
  • Evaluating the effect of IL-9 blockade on disease activity and severity.

Main Results:

  • Gut-residing T cells from IBD patients exhibit high IL-9 production.
  • IL-9 producing T cells impair intestinal epithelial barrier integrity by affecting cellular proliferation and tight junctions.
  • Blocking IL-9 significantly ameliorated disease activity and severity in experimental colitis.

Conclusions:

  • IL-9 producing T cells are critical contributors to IBD pathogenesis.
  • Targeting IL-9 represents a potential novel therapeutic strategy for inflammatory bowel diseases.